FOSTER CITY, Calif.--(BUSINESS WIRE)--Entelos, Inc. (LSE:ENTL - News) announced today that Pfizer (NYSE:PFE - News) has signed an agreement with Entelos to continue research using the Entelos® Cardiovascular PhysioLab® platform, originally built in collaboration with Pfizer. Financial terms were not disclosed.
“The pharmaceutical and medical communities recognize the importance of treating complex conditions much earlier in the disease process,” stated James Karis, president and CEO of Entelos. “We expect to use our new cardiovascular platform to conduct research that goes much deeper into the biology of heart disease to help identify novel approaches and treatments.”
Notes to Editors
About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company building predictive in silico disease models and using “virtual patients” to revolutionize the way medicines are discovered, developed, and utilized. The Company’s predictive computer models, known as PhysioLab® systems, are used to validate novel drug targets, select and develop compounds, assess safety, optimize clinical trials and combination therapies, reprofile drugs, evaluate in-licensing candidates, and better position existing products in competitive markets. In addition to internal programs, Entelos partners with global pharmaceutical and biotechnology companies and currently provides scientific expertise and models in such areas as cardiovascular disease, asthma, obesity, diabetes and rheumatoid arthritis, and complex physiological processes such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization.
Contact: Entelos, Inc. Jill Fujisaki, Vice President, Investor Relations Tel: +1-650-572-5430 fujisaki@entelos.com or Brunswick Group Justine McIlroy or Alex Tweed or Jon Coles Tel: +44-207404-5959
Source: Entelos, Inc.
